Michael Megaly to Drug-Eluting Stents
This is a "connection" page, showing publications Michael Megaly has written about Drug-Eluting Stents.
Connection Strength
4.289
-
Utilization of Non-Drug-Eluting Devices for Inpatient Percutaneous Coronary Intervention in the United States. Am J Cardiol. 2023 01 01; 186:209-215.
Score: 0.736
-
Outcomes With Drug-Coated Balloons vs. Drug-Eluting Stents in Small-Vessel Coronary Artery Disease. Cardiovasc Revasc Med. 2022 02; 35:76-82.
Score: 0.658
-
Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis. Cardiovasc Revasc Med. 2021 02; 23:28-35.
Score: 0.632
-
Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis. Cardiovasc Revasc Med. 2021 01; 22:29-33.
Score: 0.624
-
Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. Catheter Cardiovasc Interv. 2021 01 01; 97(1):32-38.
Score: 0.606
-
Outcomes with drug-coated balloons in small-vessel coronary artery disease. Catheter Cardiovasc Interv. 2019 04 01; 93(5):E277-E286.
Score: 0.561
-
Etravirine as a culprit of recurrent drug-eluting in-stent restenosis in an HIV patient. Int J Cardiol. 2016 Sep 15; 219:117-8.
Score: 0.473